Pospísilová Y, Adam Z
Interní hematoonkologická klinika Lékarské fakulty MU a FN Brno.
Vnitr Lek. 2007 Jan;53(1):18-23.
A deterioration of glucose tolerance is one of the most important side-effects ofglucocorticoid therapy. Disorders of glucose metabolism are present in almost all patients treated with glucocorticoids and 25% of these develop manifest diabetes mellitus. Glucocorticoids increase gluconeogenesis in hepatis and decrease insulinosensitivity in peripheral tissues and probably also decrease the release of insulin from pancreatic beta cells. The deterioration of glucose tolerance leads to worsening of morbidity and mortality of seriously ill patients. In glucocorticoid-induced diabetes mellitus the highest levels of glucose are seen in the afternoon, in the evening and postprandially: Normal levels of glucose are seen in the morning. Excluding 11 patients with diabetes (16%), we idenfied 7 (10%) patients with normal glucose tolerance, 13 (19%) patients with impaired fasting glucose or/and impaired glucose tolerance and glucocorticoid-induced diabetes mellitus we found in 37 (55%) patients treated in our department with diagnosis of myeloma multiplex in the year 2004 intermitently with 40 mg dexamethason p.o.
糖耐量恶化是糖皮质激素治疗最重要的副作用之一。几乎所有接受糖皮质激素治疗的患者都存在糖代谢紊乱,其中25%会发展为显性糖尿病。糖皮质激素会增加肝脏的糖异生,降低外周组织的胰岛素敏感性,还可能减少胰腺β细胞释放胰岛素。糖耐量恶化会导致重症患者的发病率和死亡率上升。在糖皮质激素诱发的糖尿病中,下午、晚上和餐后血糖水平最高,早晨血糖水平正常。排除11例糖尿病患者(16%)后,我们确定7例(10%)糖耐量正常,13例(19%)空腹血糖受损或/和糖耐量受损,在2004年我们科室诊断为多发性骨髓瘤且间歇性口服40毫克地塞米松治疗的37例(55%)患者中发现了糖皮质激素诱发的糖尿病。